Age Was Associated With CBD Exposure Per Dose in an Epilepsy Cohort
Adults had higher CBD concentration-to-dose ratios than children in an epilepsy pharmacokinetic cohort summarized by a review. Weight-adjusted dosing therefore did not eliminate all age-related exposure differences in that sample.
The study measured plasma concentrations
The review describes Contin and colleagues’ assessment of 43 patients with drug-resistant Dravet or Lennox–Gastaut syndrome in an expanded-access program. Patients received highly purified oral CBD.
Plasma exposure was associated with weight-adjusted daily dose. The review also reports approximately 32% higher concentration-to-dose ratios in adults than children. The observation concerns measured systemic exposure, not a direct comparison of seizure benefit.
Dose, concentration and response remain different
A dose expressed per kilogram accounts for body weight mathematically. It does not guarantee identical absorption or disposition across ages. A concentration-to-dose ratio can help describe those differences without proving their mechanism.
The cohort result does not supply a universal adjustment percentage for an individual. Small observational groups, sampling times and clinical circumstances constrain that application.
Avoid extending the result to impairment
Plasma CBD measurements are not whole-blood THC measurements and cannot be used as a THC-impairment threshold. Nor does higher exposure automatically mean greater benefit or toxicity.
The useful question is whether the clinical claim concerns administered amount, measured concentration or an actual patient outcome. The review summary supports attention to age in exposure research, rather than a self-directed dosing rule.
Related: Separating cannabis exposure from impairment.
Research cited
Șolea R; Șerban E; Călugăr-Solea SF; et al.. Pharmaceuticals (2026). Cannabis and Cannabinoids: The Medical Potential of Cannabidiol in Mental and Neurological Disorders.
